Author

The brewing industry is a very, very male dominated industry. It's a male bastion.

I am very concerned about the fact that India as a country does not have a national health system, and I am determined to try and influence the government to really build a national health system for the country.

From Kiran Mazumdar-Shaw

When I started Biocon in 1978, the obstacles I needed to navigate were manifold - ranging from infrastructural hurdles to issues related to my credibility as a business woman. With no access to venture capital, money was scarce and high-cost, debt-based capital was all I had.

From Kiran Mazumdar-Shaw

My passion for innovation and my interest in the 'business of science' has seen Biocon commercialize many innovative platforms and products.

From Kiran Mazumdar-Shaw

Indian business women like Indra Nooyi, Chanda Kochhar, Naina Lal Kidwai, Shikha Sharma, Swati Piramal, Anu Agha, Swati Piramal, Sulajja Firodia Motwani and Zia Mody have put India on the global firmament.

From Kiran Mazumdar-Shaw

As a traditionally risk-averse nation, India has rarely been at the forefront of innovation. Indian companies have mostly imitated others and became very good at it.

From Kiran Mazumdar-Shaw

What really got me focused on cancer was when my best friend was diagnosed with breast cancer, and even though she was a well-to-do person, I found that her treatment costs were crippling.

From Kiran Mazumdar-Shaw

I faced a number of challenges whilst I built Biocon. Initially, I had credibility challenges where I couldn't get banks to fund me; I couldn't recruit people to work for a woman boss. Even in the businesses where I had to procure raw materials, they didn't want to deal with women.

From Kiran Mazumdar-Shaw

As you become more successful, the gender barrier disappears. The credibility challenges you have during your growing up years starts disappearing when you start demonstrating success.

From Kiran Mazumdar-Shaw

Unfortunately, our stock is somehow not well understood by the markets. The market compares us with generic companies. We need to look at Biocon as a bellwether stock. A stock that is differentiated, a stock that is focused on R&D, and a very, very strong balance sheet with huge value drivers at the end of it.

From Kiran Mazumdar-Shaw

Kiran Mazumdar-Shaw

Notable Quotes

Authors with Similar Views

Bill Gates

Ryan Bethencourt

Craig Venter

Romesh Wadhwani

Baba Kalyani

Authors with Opposing Views

Alex Grey

Andrej Pejic

David Soul

Dionne Warwick

Frank McCourt